Captopril

Indications and usage: Hypertension: Captopril tablets, USP, are indicated for the treatment of hypertension. In using captopril tablets, USP, consideration should be given to the risk of neutropenia/agranulocytosis . Captopril tablets, USP may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations.

CLINICAL PHARMACOLOGY Mechanism of Action The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide.

Clinical clearance of Captopril (Angiotensin Converting Enzyme Inhibitor) relies on predominantly hepatic biotransformation with renal elimination of polar captopril conjugates with a Steady-state plasma equilibrium reached over 9–22 hour t½ intervals for Captopril half-life; patients absorbing at Approximately 75% to 87% enteral uptake across labeled Captopril strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–5 hours after captopril dosing.

FDA clinical labeling for Captopril restricts administration in do not co-administer aliskiren with captopril in patients with diabetes .; confirmed ige-mediated allergy or cutaneous reaction to captopril (captopril) components across 12.5 mg/1 Tablet, 25 mg/1 Tablet, 100 mg/1 Tablet, 50 mg/1 Tablet, 100mg Tablet, with self-reported patient tracking dominated by dizziness (7.1% of reports), headache (7% of reports), fatigue (5.1% of reports).